<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313477899</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313477899</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Iwata</surname><given-names>S</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Saito</surname><given-names>K</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Tokunaga</surname><given-names>M</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tanaka</surname><given-names>Y</given-names></name>
<xref ref-type="corresp" rid="corresp1-0961203313477899"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203313477899">The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan</aff>
<author-notes>
<corresp id="corresp1-0961203313477899">Yoshiya Tanaka, The First Department of Internal Medicine, School of Medicine, University of Occupational &amp; Environmental Health, Japan, 1–1 Iseigaoka, Yahata-nishi, Kitakyushu 807–8555, Japan. Email: <email>tanaka@med.uoeh-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>538</fpage>
<lpage>540</lpage>
<history>
<date date-type="received"><day>2</day><month>12</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<custom-meta-wrap>
<custom-meta>
<meta-name>edited-state</meta-name>
<meta-value>corrected-proof</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Sir, Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease induced by autoreactive T cell activation and autoantibody overproduction by B cells. Rituximab produces B cell depletion in patients with refractory SLE.<sup><xref ref-type="bibr" rid="bibr1-0961203313477899">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr8-0961203313477899">8</xref></sup> However, the precise mechanism of rituximab induced long-term SLE remission remains unknown.</p>
<p>We investigated the phenotypic changes in lymphocytes in six patients with SLE refractory to high-dose corticosteroid and immunosuppressants including cyclophosphamide (four with lupus nephritis (WHO type I:1, type IV:3) and four with neuropsychiatric (NP)-SLE (two with both lupus nephritis and NP-SLE)). They had been in remission for 6 years since receiving rituximab. Patients’ numbers (#1, 2, 3, 4, 5, 7) and their clinical background were matched with those used in our previous study.<sup><xref ref-type="bibr" rid="bibr9-0961203313477899">9</xref></sup> Dose of rituximab was 375 mg/m<sup>2</sup> every 2 weeks referred to therapeutic dose of lymphoma 375 mg/m<sup>2</sup> weekly (4–8 weeks). Written informed consent was obtained from each patient and the study was approved by the ethics committee of our university.</p>
<p><xref ref-type="fig" rid="fig1-0961203313477899">Figure 1A</xref> shows a representative patient with long-term remission (Patient #4). Rituximab resulted in the disappearance of peripheral blood CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>−</sup> naïve B cells, CD19<sup>+</sup>IgD<sup>−</sup>CD27<sup>+</sup> class-switched memory B cells and CD19<sup>+</sup>IgD<sup>−</sup>CD27<sup>−</sup> memory B cells within 4 weeks. However, recovery of naïve B cells occurred within 3–9 months and persisted for 2–6 years, whereas memory B and plasma cells remained depleted through 0.5–6 years. The disappearance of memory B and plasma cells was observed in all six patients with long-term remission of SLE. Rituximab increased CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>−</sup> naive B cells (mean ± SD: 42.0 ± 18.0% to 86.5 ± 5.8% (p &lt; 0.05) to 87.8 ± 5.2% (p &lt; 0.05)) and reduced CD19<sup>+</sup>IgD<sup>−</sup>CD27<sup>+</sup> class-switched memory B cells (29.4 ± 7.2% to 6.5 ± 2.6% (p &lt; 0.05) to 5.0 ± 3.5% (p &lt; 0.05)) and CD19<sup>+</sup>IgD<sup>−</sup>CD27<sup>−</sup> memory B cells (26.9 ± 15.3% to 5.9 ± 3.0% (p &lt; 0.05) to 5.7 ± 3.2% (p &lt; 0.05)) at 6 years after rituximab treatment. On the other hand, CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup> memory B cells remained low at 6 years after treatment with rituximab (1.7 ± 0.6% to 1.0 ± 0.8% to 1.6 ± 1.4%). Little is known about the origin of CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup> memory B cells, which are thought to be related to splenic marginal-zone B cells since they have similar phenotypic markers with different requirements for Ig receptor mutation.<sup><xref ref-type="bibr" rid="bibr10-0961203313477899">10</xref></sup>
<fig id="fig1-0961203313477899" position="float"><label>Figure 1</label><caption><p>Changes in subsets and expression of costimulatory molecules on CD19<sup>+</sup>and CD4<sup>+</sup>cells in patients with SLE and prolonged remission at 6 years after treatment with rituximab therapy. (A) <italic>Left top:</italic> subsets on CD19<sup>+</sup>cells immediately before and 2 and 6 years after rituximab treatment in Patient 4 (a representative patient following a typical course). Peripheral blood mononuclear cells were gated on CD19<sup>+</sup> cells and further separated with IgD and CD27. <italic>Left upper quadrant:</italic> plasma cells (CD27<sup>++</sup>) and class-switched memory B cells (CD27<sup>+</sup>). <italic>Right upper quadrant:</italic> IgM memory B cells. <italic>Left lower quadrant:</italic> double-negative memory B cells. <italic>Right lower quadrant:</italic> naïve B cells. <italic>Left bottom:</italic> changes in the percentage of each subset of CD19<sup>+</sup> cells in six patients with long-term remission. <italic>Right:</italic> CD19<sup>+</sup> cell subset in these six patients at 6 years. (B) <italic>Top:</italic> expression of costimulatory molecule CD80 on CD19-positive cells in the same patient. <italic>Bottom:</italic> changes in percentage of CD80<sup>+</sup> cells among CD19<sup>+</sup> cell population in the six patients with long-term remission. (C) Longitudinal changes in percentages of CD45RO<sup>+</sup> cells among CD4+ cells, absolute number of CD4<sup>+</sup> cells, absolute number of CD4<sup>+</sup>CD45RA<sup>+</sup> cells, and absolute number of CD4<sup>+</sup>CD45RO<sup>+</sup> cells. (D) Changes in percentages of CD40L<sup>+</sup> cells and ICOS<sup>+</sup> cells among CD4<sup>+</sup> cell population in the six patients with prolonged remission. Data are mean ± SD of six patients.</p></caption><graphic xlink:href="10.1177_0961203313477899-fig1.tif"/>
</fig></p>
<p>During the same period, SLE remained in remission and the mean dose of corticosteroid was tapered from 35.0 to 2.9 mg/day. We reported that rituximab therapy rapidly decreased CD19<sup>+</sup> cells bearing CD80,<sup><xref ref-type="bibr" rid="bibr9-0961203313477899">9</xref></sup> but a significant reduction from baseline levels was still noted at 2 and 6 years in CD80-expressing cells among the CD19<sup>+</sup> cells (59.9 ± 30.4% to 9.8 ± 5.4% (p &lt; 0.05) to 9.6 ± 2.9% (p &lt; 0.05)) (<xref ref-type="fig" rid="fig1-0961203313477899">Figure 1B</xref>). Furthermore, the number of CD4<sup>+</sup> T cells (207 ± 53.0 to 340 ± 139.3 (p &lt; 0.05) to 380.3 ± 209.5 (p &lt; 0.05) cells/µl) and CD45RO<sup>−</sup>naïve T cells (72.1 ± 36.2 to 185 ± 104.9 (p &lt; 0.05) to 170 ± 108.1 (p &lt; 0.05) cells/µl) increased significantly (<xref ref-type="fig" rid="fig1-0961203313477899">Figure 1C</xref>) and the expression of costimulatory molecules CD40L (9.9 ± 7.8% to 2.1 ± 0.9% (p &lt; 0.05) to 2.6 ± 0.7% (p &lt; 0.05)) and ICOS (9.6 ± 4.9% to 2.7 ± 1.8% (p &lt; 0.05) to 3.3 ± 1.6% (p &lt; 0.05)) on CD4<sup>+</sup> cells remained down-regulated at 2 and 6 years in the six rituximab-treated patients (<xref ref-type="fig" rid="fig1-0961203313477899">Figure 1D</xref>).</p>
<p>The above results indicate that rituximab induced characteristic phenotypic changes within 6 years in patients with remission: decrease in memory B cells, plasma cells, and CD80-positive B cells, increase in CD4+ naïve, and decrease in CD40L and ICOS on CD4+ T cells. Taken together, we suggest that activated T cells, in addition to activated B cells, seem to be involved in the pathogenesis of SLE and that activated B−T cell interaction may worsen the pathophysiology of SLE. B cell recovery following rituximab treatment in SLE is associated with a delay in peripheral blood memory B cell recovery that correlates with a reconstitution dominated by an expansion of naive B cells. The severely delayed maturation and/or expansion of memory B cells might, therefore, lead to the inhibition of T cell activation and differentiation mediated by memory B cells through costimulatory molecules. Thus, the reconstitution of peripheral B cells and the possible inactivation of T cells may result in the long-term remission of the disease after the treatment with rituximab in patients with SLE.</p>
</body>
<back>
<sec id="sec1-0961203313477899"><title>Funding</title>
<p>This work was supported in part by a Research Grant-In-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the University of Occupational and Environmental Health, Japan.</p>
</sec>
<sec id="sec2-0961203313477899"><title>Conflict of interest</title>
<p>Dr. Tanaka has received consulting fees, lecture fees, and/or honoraria from Mitsubishi-Tanabe Pharma, Chugai Pharma, Eisai Pharma, Pfizer, Abbott Immunology Pharma, Daiichi-Sankyo, Janssen Pharma, Astra-Zeneca, Takeda Industrial Pharma, Astellas Pharma, Asahi-kasei Pharma and GlaxoSmithKline and has received research grant support from Mitsubishi-Tanabe Pharma, Bristol-Myers Squibb, Takeda Industrial Pharma, MSD, Astellas Pharma, Eisai Pharma, Chugai Pharma, Pfizer and Daiichi-Sankyo. All other authors declare no conflict of interest.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Ms. T. Adachi, Ms. N. Sakaguchi, and Ms. K. Noda for the excellent technical assistance.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313477899"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Looney</surname><given-names>RJ</given-names></name><name><surname>Anolik</surname><given-names>JH</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab</article-title>. <source>Arthritis Rheum</source> <year>2004</year>; <volume>50</volume>: <fpage>2580</fpage>–<lpage>2589</lpage>.</citation></ref>
<ref id="bibr2-0961203313477899"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leandro</surname><given-names>MJ</given-names></name><name><surname>Edwards</surname><given-names>JC</given-names></name><name><surname>Cambridge</surname><given-names>G</given-names></name><name><surname>Ehrenstein</surname><given-names>MR</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>An open study of B lymphocyte depletion in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2002</year>; <volume>46</volume>: <fpage>2673</fpage>–<lpage>2677</lpage>.</citation></ref>
<ref id="bibr3-0961203313477899"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rastetter</surname><given-names>W</given-names></name><name><surname>Molina</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>CA</given-names></name></person-group>. <article-title>Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases</article-title>. <source>Annu Rev Med</source> <year>2004</year>; <volume>55</volume>: <fpage>477</fpage>–<lpage>503</lpage>.</citation></ref>
<ref id="bibr4-0961203313477899"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anolik</surname><given-names>J</given-names></name><name><surname>Sanz</surname><given-names>I</given-names></name><name><surname>Looney</surname><given-names>RJ</given-names></name></person-group>. <article-title>B cell depletion therapy in systemic lupus erythematosus</article-title>. <source>Curr Rheumatol Rep</source> <year>2003</year>; <volume>5</volume>: <fpage>350</fpage>–<lpage>356</lpage>.</citation></ref>
<ref id="bibr5-0961203313477899"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus</article-title>. <source>Mod Rheumatol</source> <year>2007</year>; <volume>17</volume>: <fpage>191</fpage>–<lpage>197</lpage>.</citation></ref>
<ref id="bibr6-0961203313477899"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab</article-title>. <source>Rheumatology (Oxford)</source> <year>2005</year>; <volume>44</volume>: <fpage>176</fpage>–<lpage>182</lpage>.</citation></ref>
<ref id="bibr7-0961203313477899"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Kawabata</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system</article-title>. <source>Ann Rheum Dis</source> <year>2007</year>; <volume>66</volume>: <fpage>470</fpage>–<lpage>475</lpage>.</citation></ref>
<ref id="bibr8-0961203313477899"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>TY</given-names></name><name><surname>Ng</surname><given-names>KP</given-names></name><name><surname>Cambridge</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>61</volume>: <fpage>482</fpage>–<lpage>487</lpage>.</citation></ref>
<ref id="bibr9-0961203313477899"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Tokunaga</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab</article-title>. <source>J Rheumatol</source> <year>2011</year>; <volume>38</volume>: <fpage>633</fpage>–<lpage>641</lpage>.</citation></ref>
<ref id="bibr10-0961203313477899"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>S</given-names></name><name><surname>Braun</surname><given-names>MC</given-names></name><name><surname>Tan</surname><given-names>BK</given-names></name><etal/></person-group>. <article-title>Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immuno- globulin repertoire</article-title>. <source>Blood</source> <year>2004</year>; <volume>104</volume>: <fpage>3647</fpage>–<lpage>3654</lpage>.</citation></ref>
</ref-list>
</back>
</article>